AVN-101

AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it is in phase II clinical trials for these indications.[2][3][4]

AVN-101
Identifiers
ChemSpider
ChEMBL
Chemical and physical data
FormulaC21H24N2
Molar mass304.437 g·mol−1
3D model (JSmol)

See also

References
  1. V. Ivachtchenko, Alexandre; A. Ivanenkov, Yan (2013). "Small Molecule 5-HT6R Ligands: A Comprehensive Insight into their Selectivity and Activity". Current Bioactive Compounds. 9 (1): 64–100. doi:10.2174/1573407211309010007. ISSN 1573-4072.
  2. Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews Drug Discovery. 12 (9): 667–687. doi:10.1038/nrd4075. ISSN 1474-1776. PMC 4176700. PMID 23989795.
  3. Benhamú, Bellinda; Martín-Fontecha, Mar; Vázquez-Villa, Henar; Pardo, Leonardo; López-Rodríguez, María L. (2014). "Serotonin 5-HT6Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease". Journal of Medicinal Chemistry. 57 (17): 7160–7181. doi:10.1021/jm5003952. ISSN 0022-2623. PMID 24850589.
  4. AdisInsight. "AVN 101". Retrieved 2015-06-10.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.